Ark appeals negative EU decision on brain cancer gene therapy Cerepro
This article was originally published in Scrip
Executive Summary
Ark Therapeutics has appealed the CHMP's negative decision on its experimental brain cancer therapy Cerepro (sitimagene ceradenovec), which the company is hoping will become the first-approved gene therapy in the EU.